Pharmacodynamics and clinical use of guanethidine, bretylium and methyldopa.
D000578:Amidines / Q000628:therapy*; D000995:Antitubercular Agents / Q000628:therapy*; D001949:Bretylium Compounds; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives; D006145:Guanethidine; D006801:Humans; D006973:Hypertension / Q000628:therapy*; D008190:Lyases / Q000037:antagonists & inhibitors*; D008750:Methyldopa; D013565:Sympatholytics / Q000628:therapy*
D000578:Amidines; D000995:Antitubercular Agents; D001949:Bretylium Compounds; D013565:Sympatholytics; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D008190:Lyases; C045166:bretylium; D006145:Guanethidine
AMIDINES/therapy; ANTITUBERCULAR AGENTS/therapy; DESMOLASES/antagonists; DOPA/related compounds; HYPERTENSION/therapy; SYMPATHOLYTICS/therapy